DDInter32 DDInter1435
Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label]. For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test. Gilotrif (afatinib) is the first FDA-approved oncology product from Boehringer Ingelheim.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Afatinib {u} (Compound) resembles {v} (Compound) Gefitinib
Afatinib {u} (Compound) binds {v} (Gene) ABCB1
Afatinib {u} (Compound) upregulates {v} (Gene) MTHFD2
Afatinib {u} (Compound) is included by {v} (Pharmacologic Class) Protein Kinase Inhibitors
Afatinib {u} (Compound) downregulates {v} (Gene) IGFBP2
Afatinib {u} (Compound) causes {v} (Side Effect) Diarrhoea
Afatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fosphenytoin
Afatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glasdegib
Afatinib {u} may lead to a major life threatening interaction when taken with {v} Lomitapide
Afatinib {u} (Compound) binds {v} (Gene) and {u} (Compound) downregulates {v} (Gene) ERBB2
Afatinib (Compound) resembles Gefitinib (Compound)
Afatinib (Compound) binds ABCB1 (Gene)
Afatinib (Compound) upregulates MTHFD2 (Gene)
Afatinib (Compound) is included by Protein Kinase Inhibitors (Pharmacologic Class)
Afatinib (Compound) downregulates IGFBP2 (Gene)
Afatinib (Compound) causes Diarrhoea (Side Effect)
Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin
Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Afatinib may lead to a major life threatening interaction when taken with Lomitapide
Afatinib (Compound) binds ERBB2 (Gene) and Afatinib (Compound) downregulates ERBB2 (Gene)